Origin and Evolution of the 2019 Novel Coronavirus

Zhang, Liangsheng; Shen, Fu‐Ming; Chen, Fei; Zhang, Lin

doi:10.1093/cid/ciaa112

Cited by 207 publications

(152 citation statements)

References 4 publications

Supporting

Mentioning

141

Contrasting

Unclassified

Order By: Relevance

“…These four co-mutations are prevalent in viral isolates from Europe. Strains from Abruzzo show 28144T in the ORF8 protein sequence, thus they have a leucin residue at position 84 in that accessory protein, and 8782C (S75 in nsp4); thus, these strains may be classified as S type [17]. All sequences obtained in this study, but one, had 27046C (T175 in the coded M protein); one sequence from Pescara, which was not deposited with GISAID, had the mutation C27046T (T175M in the M protein).…”

Section: Resultsmentioning

confidence: 99%

A “One-Health” approach for diagnosis and molecular characterization of SARS-CoV-2 in Italy

et al. 2020

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

A “One-Health” approach for diagnosis and molecular characterization of SARS-CoV-2 in Italy

et al. 2020

View full text Add to dashboard Cite

“…This provokes people to explore the difference of the host tropism and transmission between SARS-CoV-2 and SARS-CoV or conduct further investigations on the potential therapeutic targets. Zhang et al [24] analyzed the genotypes of COVID-19 in different patients from several provinces and found that SARS-CoV-2 had been mutated in different patients in China. Although the degree of diversification of SARS-CoV-2 is smaller than the mutation of H7N9 avian influenza [25].…”

Section: Genome Structure and Key Viral Factorsmentioning

confidence: 99%

The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status

et al. 2020

View full text Add to dashboard Cite

An acute respiratory disease, caused by a novel coronavirus (SARS-CoV-2, previously known as 2019-nCoV), the coronavirus disease 2019 (COVID-19) has spread throughout China and received worldwide attention. On 30 January 2020, World Health Organization (WHO) officially declared the COVID-19 epidemic as a public health emergency of international concern. The emergence of SARS-CoV-2, since the severe acute respiratory syndrome coronavirus (SARS-CoV) in 2002 and Middle East respiratory syndrome coronavirus (MERS-CoV) in 2012, marked the third introduction of a highly pathogenic and large-scale epidemic coronavirus into the human population in the twenty-first century. As of 1 March 2020, a total of 87,137 confirmed cases globally, 79,968 confirmed in China and 7169 outside of China, with 2977 deaths (3.4%) had been reported by WHO. Meanwhile, several independent research groups have identified that SARS-CoV-2 belongs to β-coronavirus, with highly identical genome to bat coronavirus, pointing to bat as the natural host. The novel coronavirus uses the same receptor, angiotensin-converting enzyme 2 (ACE2) as that for SARS-CoV, and mainly spreads through the respiratory tract. Importantly, increasingly evidence showed sustained human-to-human transmission, along with many exported cases across the globe. The clinical symptoms of COVID-19 patients include fever, cough, fatigue and a small population of patients appeared gastrointestinal infection symptoms. The elderly and people with underlying diseases are susceptible to infection and prone to serious outcomes, which may be associated with acute respiratory distress syndrome (ARDS) and cytokine storm. Currently, there are few specific antiviral strategies, but several potent candidates of antivirals and repurposed drugs are under urgent investigation. In this review, we summarized the latest research progress of the epidemiology, pathogenesis, and clinical characteristics of COVID-19, and discussed the current treatment and scientific advancements to combat the epidemic novel coronavirus.

show abstract

“…Based on the phylogenetic analysis of the genomic data of SARS-CoV-2, Zhang et al indicated that the SARS-CoV-2 is most closely related to two SARS-CoV sequences isolated from bats in 2015 and 2017. This is suggestive that the bat's CoV and SARS-CoV-2 share a common ancestor, and the new virus can be considered as a SARS-like virus [7].…”

Section: Introductionmentioning

confidence: 94%

Structural and Evolutionary Analysis Indicate that the SARS-CoV-2 Mpro is an Inconvenient Target for Small-Molecule Inhibitors Design

Bzówka

Mitusińska

Raczyńska

et al. 2020

Preprint

View full text Add to dashboard Cite

The novel coronavirus whose outbreak took place in December 2019 continues to spread at a rapid rate worldwide. In the absence of an effective vaccine, inhibitor repurposing or de novo design may offer a longer-term strategy to combat this and future infections due to similar viruses. Here, we report on detailed molecular dynamics simulations of the main protease (Mpro). We compared and contrasted the Mpro for COVID-19 with a highly similar SARS protein. In spite of a high level of sequence similarity, the active sites in both proteins show major differences in both shape and size indicating that repurposing SARS drugs for COVID-19 may be futile. Furthermore, analysis of the pocket's time-dependence indicates its flexibility and plasticity, which dashes hopes for rapid and reliable drug design. Conversely, structural stability of the protein with respect to flexible loop mutations indicates that the virus' mutability will pose a further challenge to the rational design of small-molecule inhibitors.

show abstract

Origin and Evolution of the 2019 Novel Coronavirus

Cited by 207 publications

References 4 publications

A “One-Health” approach for diagnosis and molecular characterization of SARS-CoV-2 in Italy

A “One-Health” approach for diagnosis and molecular characterization of SARS-CoV-2 in Italy

The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status

Structural and Evolutionary Analysis Indicate that the SARS-CoV-2 Mpro is an Inconvenient Target for Small-Molecule Inhibitors Design

Contact Info

Product

Resources

About